Interestingly, the maximum serum concentration of KCL-HO-1i achieved through oral delivery was 18-fold lower than with intraperitoneal (i.p.)delivery but still delivered equivalent tumor control, suggesting that the therapeutic concentration of KCL-HO-1i may be lower than anticipated. This evidence concerns the gene HMOX1 and neoplasm.